Advent International and Singapore sovereign investor GIC have offered to buy booming rare-disease drugmaker Swedish Orphan Biovitrum in a deal valuing the business at about $8bn.
The post Booming rare disease drugmaker SOBI valued at $8bn through Advent, GIC buyout offer first appeared on AltAssets Private Equity News.
